News & Events

• September 17, 2019
  

  C-Path and NORD Rare Disease Cures Accelerator Data and Analytics Platform Launch, Tuesday, Sept. 17, Bethesda, MD

  C-Path and the National Organization for Rare Disorders^® will host a meeting to formally launch development of a new rare disease data and analytics platform. Funded by a cooperative agreement through the U.S. Food and Drug Administration, the goal of the platform is to accelerate the movement of therapies from bench to bedside for rare diseases.

  Register here.

• August 14, 2019
  Conrado et al. 2019 Towards Regulatory Endorsement

  Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy.
• August 7, 2019
  

  Funded by FDA, C-Path and NORD to Launch Rare Disease Data and Analytics Platform

  C-Path and NORD Rare Disease Cures Accelerator Data Analytics Platform Launch, Tuesday, Sept. 17, Bethesda, MD

  C-Path and the National Organization for Rare Disorders® will host a meeting to formally launch development of a new rare disease data and analytics platform. Funded by a cooperative agreement through the U.S. Food and Drug Administration, the goal of the platform is to accelerate the movement of therapies from bench to bedside for rare diseases. Register here.  

• July 14, 2019 - July 18, 2019
  

  Poster Presentation at the 2019 Alzheimer’s Association International Conference, July 14-18, 2019, Los Angeles, CA

  The Alzheimer’s Association International Conference (AAIC) is an important annual scientific meeting where international investigators, clinicians and care providers gather to share the latest study results, theories and discoveries that will help bring the world closer to breakthroughs in dementia science. This year’s conference will be hosted in Los Angeles, CA, between July 14th and 18th.

  Each year, on behalf of our consortium members, CPAD attends AAIC to share the consortium’s vision, goals, and latest milestones of our work with the research community, to educate ourselves on latest developments and trends, and to meet and exchange information with our members and other key opinion leaders. This year, one poster (P4-253) was accepted for presentation.

• July 2, 2019
  

  C-Path Taps Medical Science Operations Executive Kristen Swingle as Chief Operating Officer

  TUCSON, Ariz., July 2, 2019 — The Critical Path Institute (C-Path) is pleased to announce that after an extensive search, it has appointed Kristen Swingle as its new Chief Operating Officer, effective July 1, 2019.

  Swingle, who previously served as Vice President of Stem Cell Operations for Cord Blood Registry (CBR), a part of California Cryobank Life Sciences, specialized in newborn stem cell collection, processing and cryopreservation, brings nearly two decades’ worth of experience in the medical and molecular sciences industry to bear in her new role as she leads the daily operations of the organization and development and implementation of C-Path’s global strategy and goals.